CENCORA, INC. (COR): what the price assumes

In the published model solve dated 2026-Q2, anchored at $322.03, CENCORA, INC. (COR) is priced for +7.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/COR

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.4%); the inversion above states its own rate.

Per-Model Detail (n=11)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Cencora moves roughly $328.7 billion of pharmaceuticals a year and keeps about 1.2% of it as trailing operating profit, so the entire investment case rests on a very thin slice of a very large number.
• Customer concentration is the defining risk, with the 10-K stating that Walgreens and Boots together accounted for approximately 25% of our revenue in fiscal 2025 and that Our top ten customers, including governmental agencies, represented approximately 66% of revenue in fiscal 2025.
• Human Health supplies about 89% of the business and Alliance Healthcare most of the rest, and the next read on both is third-quarter fiscal 2026 results on August 5, 2026.

Bull Case

The direction of travel is the argument here, and it is easiest to see by putting two growth rates side by side. In the quarter ended March 31, 2026, revenue rose $2.9 billion, or 3.8%. Gross profit rose $528.5 million, or 17.3%. When the profit line grows more than four times as fast as the sales line in a distribution business, something has changed in what is being distributed, not just how much. Reported operating income followed, at $1,142.6 million against $1,036.2 million in the same quarter a year earlier.

What changed is mix, and the filings name it. In fiscal 2025 the U.S. business grew revenue by $25.6 billion, or 9.7%, on volume that included increased sales of specialty products to health systems and physician practices and increased sales of products labeled for diabetes. Specialty drugs and the newer metabolic medicines are handled differently from a bottle of generic statins: cold chain, tighter compliance, narrower distribution rights, more service wrapped around each unit. The distributor gets paid more for the harder job.

The international side is compounding faster still. International Healthcare Solutions revenue increased $0.9 billion, or 13.0%, in the quarter, and its operating income increased $21.2 million, or 13.7%. Growth arriving with profit attached, rather than bought by cutting price, is the useful kind. That segment is the smaller of the two, which is precisely why its growth rate matters: it is the part of the business capable of moving the consolidated number.

Then there is the structure of the industry itself, which is unusually favourable and unusually invisible. Three companies handle most of the pharmaceuticals in the United States, and the barrier to a fourth is the very thing that looks like a weakness on the income statement. Cardinal Health (CAH) keeps a 3.70% gross margin and McKesson (MCK) 3.61%. Nobody enters a business that keeps three cents on the dollar in the hope of undercutting incumbents who have already built the warehouses, the licences and the manufacturer relationships. The thin margin is the moat.

Management has also earned some benefit of the doubt on expectations. Since 2008 they have raised guidance on 15 separate occasions and reaffirmed it on 14 more. And the starting point is not demanding: the market is paying roughly 19x trailing operating profit for a company it expects to shrink slightly, which is a low hurdle for a business whose gross profit just grew at 17.3%.

Bear Case

The advantage a wholesaler holds is being impossible to remove from a customer's supply chain. Cencora's problem is that it does not have many customers to be impossible to. The 10-K puts the arithmetic plainly: Walgreens and Boots together accounted for approximately 25% of our revenue in fiscal 2025, Evernorth Health Services accounted for approximately 13% of our revenue in fiscal 2025, and Our top ten customers, including governmental agencies, represented approximately 66% of revenue in fiscal 2025. That is not a moat around a market. It is a set of contracts with a handful of counterparties, each of them large enough to negotiate hard and sophisticated enough to know exactly what the alternative bids look like.

The erosion is already visible in the numbers. U.S. Healthcare Solutions revenue grew 2.9% last quarter, and the filing attributes part of the shortfall to a decline at a large mail order customer as a result of brand conversions. Brand conversion is the moment a branded drug goes generic and the same physical pill is suddenly worth a fraction of what it was. A distributor compensated partly on the dollar value of what it ships feels that immediately, and it has no way to stop it happening. Meanwhile the two nearest comparables have been growing faster: over their most recent reported twelve months, Cardinal Health (CAH) grew revenue 10.1% and McKesson (MCK) 12.4%.

The concentration reaches the balance sheet too. The same largest customer group accounted for approximately 38% of net accounts receivable at the fiscal year end. In a business that converts roughly 1.2% of revenue into trailing operating profit, a receivable problem at one counterparty does not shave the margin. It removes it. That is the specific fragility a thin-margin, high-turnover model carries, and it is why the credit quality of a handful of retail pharmacy chains is genuinely part of this equity's risk profile.

Leverage sharpens the same point. Net debt is $10.4 billion, about 2.73 times operating profit, against liquid assets of $2.2 billion. That is a manageable load in a stable year. It is a different proposition in a year where a large customer restructures, because the operating profit in that denominator is the thin slice, not the revenue.

On valuation, no family of methods reaches today's price. The asset-based methods land at roughly a third of it, though that comparison deserves a caveat: with book value per share of $17.39, a distributor that runs on other people's inventory and negative working capital was never going to be valued off its balance sheet. The number that carries real weight is the peer-multiple read, which puts the price about 57% above where those methods land. That is the honest bear statement. Cencora is priced at a premium to what comparable distributors fetch, in a business where the growth is currently slower than theirs and the customer list is shorter.

Valuation

Every valuation question about this company reduces to one structural fact: revenue of roughly $328.7 billion converts into a trailing operating margin of about 1.2%. Nothing else in the analysis matters as much, because a business that keeps a penny on the dollar has almost no cushion between a good year and a bad one. Today's $309.71 works out to about 19x trailing operating profit, and inverting that gives an embedded assumption of roughly -1% annual operating growth over the next five years. The market is paying for a slow fade rather than for expansion.

Measured against the references, that assumption is unremarkable. The pace sits within what Cencora has recently delivered, and the multiple sits in the lower half of the peer range. The overall read is broadly consistent with plausible outcomes, which is worth stating plainly because the individual method comparisons that follow look far more alarming than the priced-in assumption actually is.

The methods do not reach the price, and the reason is instructive rather than damning. The earnings-power methods, which capitalize current cash generation at a required return with no growth, land at a small fraction of the price; the asset-value methods land at roughly a third of it. Both are structurally hostile to this kind of company. Book value per share is $17.39, because a distributor's economics come from turning other people's inventory quickly on negative working capital rather than from owning things. The comparison that survives scrutiny is the peer-multiple one, which puts the price about 57% above where those methods land.

Against the two names that actually do the same job, the picture is mixed in a specific way. Cardinal Health (CAH) turns $244.7 billion of revenue at a 1.04% operating margin and McKesson (MCK) $403.4 billion at 1.54%. Cencora sits between them on both size and margin. Where it does not sit between them is growth: over their most recent reported twelve months CAH grew revenue 10.1% and MCK 12.4%, while Cencora's most recent quarter grew 3.8%. Paying a premium multiple to the group while growing more slowly than the group is the tension a buyer at this price is accepting.

The balance sheet neither rescues nor threatens that conclusion. Net debt of $10.4 billion sits at about 2.73 times operating profit with liquid assets of $2.2 billion, and the diluted share count has been essentially unchanged, at 195.4 million in the March 2026 quarter against 195.1 million a year earlier. This is a business funded by the float between paying manufacturers and collecting from pharmacies, which works beautifully while volumes grow and stops working the moment they do not.

Catalysts

Third-quarter fiscal 2026 results are scheduled for August 5, 2026. The line to watch is U.S. Healthcare Solutions revenue growth, which ran at 2.9% last quarter with the large mail order customer's brand conversions working against it. Whether that drag is a one-off cycle of patent expiries or the start of a slower run rate is the single question the quarter can answer.

On the commercial side, the company announced a distribution agreement with Kite, Gilead's cell therapy business, covering CAR T-cell therapies in June 2026. Cell therapies are the extreme end of the specialty logistics problem: individually manufactured, time-critical, and requiring chain-of-identity tracking from patient to patient. Those are exactly the shipments a distributor can charge properly for, and they sit alongside the OneOncology and Retina Consultants of America acquisitions that the 10-Q describes as building on its leadership in specialty pharmaceuticals.

Capital return runs on a modest cadence. The dividend is $2.40 a share annually and went ex on May 15, 2026, and a $2.0 billion repurchase authorization approved by the board in March 2024 remains the standing mechanism. Given that the diluted count has barely moved year over year, the pace of that repurchase against equity issuance is worth tracking rather than assuming. Sell-side sentiment has caught up rather than led: Bank of America raised its target to $310 from $285 in July 2026 while keeping a neutral rating, which lands essentially at the current quote.

Peer Cohorts (Per Segment, With Filing Citations)

U.S. Healthcare Solutions / International Healthcare Solutions (reported)

• CAH (Cardinal Health, Inc.)
• FY2025 10-K: …pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of…
• FY2025 10-K: …and Canada. This segment also assembles and sells sterile and non-sterile procedure kits. The GMPD segment, through its Wavemark division, also provides an automated technology platform for inventory management. Other Operating Segments Our Nuclear and Precision Health Solutions operating segment operates nuclear…
• MCK (McKESSON CORPORATION)
• FY2025 10-K: …in Canada. Refer to Financial Note 2, "Business Acquisitions and Divestitures," , to the consolidated financial statements included in this Annual Report for more information. U.S. Pharmaceutical Segment: Our U.S. Pharmaceutical segment provides distribution and logistics services for branded, generic, specialty,…
• FY2025 10-K: …enable its customers to drive greater efficiencies in their day-to-day operations, effectively managing their inventories and complying with complex government regulations. Solutions include McKesson Pharmacy Systems, MacroHelix, and Supply Logix, all of which provide innovative software technology and services that…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.